Equities analysts predict that Proteostasis Therapeutics Inc (NASDAQ:PTI) will post earnings per share of ($0.67) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Proteostasis Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.72) and the highest estimate coming in at ($0.61). Proteostasis Therapeutics reported earnings per share of ($0.38) in the same quarter last year, which indicates a negative year-over-year growth rate of 76.3%. The firm is scheduled to issue its next quarterly earnings results on Thursday, March 29th.
According to Zacks, analysts expect that Proteostasis Therapeutics will report full-year earnings of ($2.50) per share for the current financial year, with EPS estimates ranging from ($2.56) to ($2.44). For the next fiscal year, analysts forecast that the business will post earnings of ($2.36) per share, with EPS estimates ranging from ($2.82) to ($1.89). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that follow Proteostasis Therapeutics.
PTI has been the topic of several recent research reports. Robert W. Baird increased their price objective on shares of Proteostasis Therapeutics from $13.00 to $25.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 12th. Leerink Swann increased their price objective on shares of Proteostasis Therapeutics from $6.00 to $8.00 in a research note on Tuesday, December 12th. ValuEngine cut shares of Proteostasis Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Zacks Investment Research cut shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Proteostasis Therapeutics in a research note on Tuesday, December 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $16.00.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jefferies Group LLC bought a new stake in Proteostasis Therapeutics during the 4th quarter worth approximately $175,000. Jane Street Group LLC bought a new stake in Proteostasis Therapeutics during the 4th quarter worth approximately $203,000. Goldman Sachs Group Inc. raised its stake in Proteostasis Therapeutics by 364.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 51,911 shares of the company’s stock worth $243,000 after acquiring an additional 40,731 shares during the period. Dimensional Fund Advisors LP bought a new stake in Proteostasis Therapeutics during the 2nd quarter worth approximately $296,000. Finally, Rock Springs Capital Management LP raised its stake in Proteostasis Therapeutics by 50.0% during the 4th quarter. Rock Springs Capital Management LP now owns 675,000 shares of the company’s stock worth $3,935,000 after acquiring an additional 225,000 shares during the period. Institutional investors own 58.37% of the company’s stock.
Shares of Proteostasis Therapeutics (NASDAQ:PTI) traded up $0.01 during trading hours on Wednesday, hitting $2.99. 242,256 shares of the stock traded hands, compared to its average volume of 743,114. Proteostasis Therapeutics has a 52-week low of $1.41 and a 52-week high of $14.88. The company has a market cap of $102.65, a PE ratio of -1.35 and a beta of 6.35.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3229158/brokerages-anticipate-proteostasis-therapeutics-inc-pti-will-announce-earnings-of-0-67-per-share.html.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.